Bupropion/zonisamide
Bupropion/zonisamide (planned trade name Empatic) is an experimental combination drug combination for the treatment of obesity.It is being developed by Orexigen Therapeutics. It is currently at phase II testing. The combination consists of two prescription medications approved by the U.S. Food and Drug Administration (FDA) for other ailments. When mixed together and tested along with proper diet and moderate exercise, they produced a substantial weight loss effect higher than the group taking a placebo. Empatic was called Excalia before its name was changed.
Wikipage redirect
Link from a Wikipage to another Wikipage
primaryTopic
Bupropion/zonisamide
Bupropion/zonisamide (planned trade name Empatic) is an experimental combination drug combination for the treatment of obesity.It is being developed by Orexigen Therapeutics. It is currently at phase II testing. The combination consists of two prescription medications approved by the U.S. Food and Drug Administration (FDA) for other ailments. When mixed together and tested along with proper diet and moderate exercise, they produced a substantial weight loss effect higher than the group taking a placebo. Empatic was called Excalia before its name was changed.
has abstract
Bupropion/zonisamide (planned ...... a before its name was changed.
@en
بوبروبيون / زونيجران (بالإنجلي ...... calia), قبل ان يتم تغيير اسمه.
@ar
CAS number
944389-00-8
Wikipage page ID
25,719,828
page length (characters) of wiki page
Wikipage revision ID
1,011,754,927
Link from a Wikipage to another Wikipage
CAS number
class
Norepinephrine-dopamine reupta ...... tylcholine receptor antagonist
@en
component
Bupropion
@en
Zonisamide
@en
legal status
Investigational
@en
type
combo
@en
verifiedrevid
451,550,479
wikiPageUsesTemplate
subject
hypernym
comment
Bupropion/zonisamide (planned ...... a before its name was changed.
@en
بوبروبيون / زونيجران (بالإنجلي ...... calia), قبل ان يتم تغيير اسمه.
@ar
label
Bupropion/zonisamide
@en
بوبروبيون/زونيساميد
@ar